Molecular predictors of response to EGFR antibodies in colorectal cancer Astrid LièvrePierre Laurent-Puig OriginalPaper 16 October 2008 Pages: 119 - 125
Using bevacizumab and cetuximab before liver surgery Brigit GruenbergerThomas Gruenberger OriginalPaper 16 October 2008 Pages: 126 - 129
Sequential chemotherapy for advanced colorectal cancer: Should we ever start with a single cytotoxic agent? Matthew T. SeymourCornelis J. A. Punt OriginalPaper 16 October 2008 Pages: 130 - 138
Should bevacizumab be continued beyond progression in colorectal cancer? Axel GrotheyDirk ArnoldLee M. Ellis OriginalPaper 16 October 2008 Pages: 139 - 143
The future of TNM staging in rectal cancer: The era of neoadjuvant therapy Iris D. NagtegaalCorrie A. M. Marijnen OriginalPaper 16 October 2008 Pages: 147 - 154
Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group Sharlene GillDaniel J. Sargent ReviewPaper 16 October 2008 Pages: 155 - 159
Neoadjuvant or adjuvant therapy for patients with resectable liver metastases Michael A. ChotiTimothy M. Pawlik OriginalPaper 16 October 2008 Pages: 160 - 166
Irinotecan versus oxaliplatin for adjuvant colon cancer therapy: Why do the results differ? Sujatha NallapareddyS. Gail EckhardtWells Messersmith OriginalPaper 16 October 2008 Pages: 167 - 172